Lynparza Receives Additional FDA Approval for Ovarian Cancer
The PARP inhibitor olaparib (Lynparza, AstraZeneca/Merck) has received FDA approval for a broader indication in ovarian cancer cases, including a new tablet formulation that will ease women’s pill burden.
The FDA approved:
- New use of olaparib tablets as a maintenance treatment of adults with recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA status.
- New use of olaparib tablets (two tablets twice daily) as opposed to capsules (eight capsules twice daily).
Read more from Managed Care on Lynparza Receives Additional FDA Approval for Ovarian Cancer